Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

BACKGROUND: Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. METHODS: In this phase 3, rand...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:N Engl J Med
Autori principali: Baselga, José, Campone, Mario, Piccart, Martine, Burris, Howard A., Rugo, Hope S., Sahmoud, Tarek, Noguchi, Shinzaburo, Gnant, Michael, Pritchard, Kathleen I., Lebrun, Fabienne, Beck, J. Thaddeus, Ito, Yoshinori, Yardley, Denise, Deleu, Ines, Perez, Alejandra, Bachelot, Thomas, Vittori, Luc, Xu, Zhiying, Mukhopadhyay, Pabak, Lebwohl, David, Hortobagyi, Gabriel N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705195/
https://ncbi.nlm.nih.gov/pubmed/22149876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1109653
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi